Melanoma Inhibitory Activity (MIA) increases the invasiveness of pancreatic cancer cells

Cancer Cell International

Helmut Friess¹  Markus W Büchler¹  Anja K Bosserhoff²  Ahmed Guweidhi¹  Nathalia A Giese¹  Jörg Kleeff¹  Jamael El Fitori¹ 

[1] Department of General Surgery, University of Heidelberg, Germany;Institute of Pathology, University of Regensburg, Germany

关键词: tumor cell invasion;    metastasis;    invasion;    pancreatic cancer;    MIA;   

Others  :  796038
DOI  :  10.1186/1475-2867-5-3

 received in 2004-11-21, accepted in 2005-02-14,  发布年份 2005

【 摘 要 】

Background

Melanoma inhibitory activity (MIA) is a small secreted protein that interacts with extracellular matrix proteins. Its over-expression promotes the metastatic behavior of malignant melanoma, thus making it a potential prognostic marker in this disease. In the present study, the expression and functional role of MIA was analyzed in pancreatic cancer by quantitative real-time PCR (QRT-PCR), immunohistochemistry, immunoblot analysis and ELISA. To determine the effects of MIA on tumor cell growth and invasion, MTT cell growth assays and modified Boyden chamber invasion assays were used.

Results

The mRNA expression of MIA was 42-fold increased in pancreatic cancers in comparison to normal pancreatic tissues (p < 0.01). In contrast, MIA serum levels were not significantly different between healthy donors and pancreatic cancer patients. In pancreatic tissues, MIA was predominantly localized in malignant cells and in tubular complexes of cancer specimens, whereas normal ductal cells, acinar cells and islets were devoid of MIA immunoreactivity. MIA significantly promoted the invasiveness of cultured pancreatic cancer cells without influencing cell proliferation.

Conclusion

MIA is over-expressed in pancreatic cancer and has the potential of promoting the invasiveness of pancreatic cancer cells.

【 授权许可】

   
2005 El Fitori et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
• [2]Bosserhoff AK, Moser M, Hein R, Landthaler M, Buettner R: In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers. J Pathol 1999, 187:446-454.
• [3]de Vries TJ, Fourkour A, Punt CJ, Diepstra H, Ruiter DJ, van Muijen GN: Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood. Br J Cancer 1999, 81:1066-1070.
• [4]Dietz UH, Sandell LJ: Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis. J Biol Chem 1996, 271:3311-3316.
• [5]Bosserhoff AK, Kondo S, Moser M, Dietz UH, Copeland NG, Gilbert DJ, Jenkins NA, Buettner R, Sandell LJ: Mouse CD-RAP/MIA gene: structure, chromosomal localization, and expression in cartilage and chondrosarcoma. Dev Dyn 1997, 208:516-525.
• [6]Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R: Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997, 57:3149-3153.
• [7]Friess H, Ding J, Kleeff J, Fenkell L, Rosinski JA, Guweidhi A, Reidhaar-Olson JF, Korc M, Hammer J, Buchler MW: Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci 2003, 60:1180-1199.
• [8]DiMagno EP, Reber HA, Tempero MA: AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999, 117:1464-1484.
• [9]Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001, 358:1576-1585.
• [10]Warshaw AL, Fernandez-del CC: Pancreatic carcinoma. N Engl J Med 1992, 326:455-465.
• [11]Karayiannakis AJ, Syrigos KN, Polychronidis A, Simopoulos C: Expression patterns of alpha-, beta- and gamma-catenin in pancreatic cancer: correlation with E-cadherin expression, pathological features and prognosis. Anticancer Res 2001, 21:4127-4134.
• [12]Coussens LM, Werb Z: Matrix metalloproteinases and the development of cancer. Chem Biol 1996, 3:895-904.
• [13]Friess H, Guo XZ, Berberat P, Graber HU, Zimmermann A, Korc M, Buchler MW: Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases. Int J Cancer 1998, 79:349-355.
• [14]Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, Vlodavsky I, Zimmermann A, Buchler MW: Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001, 61:4655-4659.
• [15]Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995, 1:149-153.
• [16]Buchler P, Reber HA, Buchler MW, Friess H, Hines OJ: VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg 2002, 236:738-749.
• [17]Friess H, Yamanaka Y, Buchler M, Berger HG, Kobrin MS, Baldwin RL, Korc M: Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993, 53:2704-2707.
• [18]Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Buchler MW, Korc M: Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997, 3:1309-1316.
• [19]Kisker O, Onizuka S, Banyard J, Komiyama T, Becker CM, Achilles EG, Barnes CM, O'Reilly MS, Folkman J, Pirie-Shepherd SR: Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res 2001, 61:7298-7304.
• [20]Yamanaka Y, Friess H, Buchler M, Beger HG, Uchida E, Onda M, Kobrin MS, Korc M: Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 1993, 53:5289-5296.
• [21]Fidler IJ: Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1990, 50:6130-6138.
• [22]Bosserhoff AK, Echtenacher B, Hein R, Buettner R: Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo. Melanoma Res 2001, 11:417-421.
• [23]Guba M, Bosserhoff AK, Steinbauer M, Abels C, Anthuber M, Buettner R, Jauch KW: Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel 3 melanoma cells in vivo. Br J Cancer 2000, 83:1216-1222.
• [24]Bosserhoff AK, Lederer M, Kaufmann M, Hein R, Stolz W, Apfel R, Bogdahn U, Buettner R: MIA, a novel serum marker for progression of malignant melanoma. Anticancer Res 1999, 19:2691-2693.
• [25]van Groningen JJ, Bloemers HP, Swart GW: Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display. Cancer Res 1995, 55:6237-6243.
• [26]Bosserhoff AK, Stoll R, Sleeman JP, Bataille F, Buettner R, Holak TA: Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. Lab Invest 2003, 83:1583-1594.
• [27]Giese NA, Raykov Z, DeMartino L, Vecchi A, Sozzani S, Dinsart C, Cornelis JJ, Rommelaere J: Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther 2002, 9:432-442.